Home Cart Sign in  
Chemical Structure| 75747-14-7 Chemical Structure| 75747-14-7

Structure of Tanespimycin
CAS No.: 75747-14-7

Chemical Structure| 75747-14-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, showing a 100-fold higher binding affinity for tumor-derived HSP90 than normal cell-derived HSP90. Tanespimycin depletes cellular STK38/NDR1, reduces STK38 kinase activity, and downregulates the stk38 gene expression.

Synonyms: 17-AAG; NSC 330507; 17-AAG, 17 AAG, 17AAG, BAY 57-9352, BAY 579352, BAY579352, KOS-953, KOS-953, KOS-953, Tanespimycin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Wnuk, Maciej ; Del Sol-Fernández, Susel ; Błoniarz, Dominika ; Słaby, Julia ; Szmatoła, Tomasz ; Żebrowski, Michał , et al.

Abstract: The accumulation of senescent cells, a hallmark of aging and age-related diseases, is also considered as a side effect of anticancer therapies, promoting drug resistance and leading to treatment failure. The use of senolytics, selective inducers of cell death in senescent cells, is a promising pharmacological antiaging and anticancer approach. However, more studies are needed to overcome the limitations of first-generation senolytics by the design of targeted senolytics and nanosenolytics and the validation of their usefulness in biological systems. In the present study, we have designed a nanoplatform composed of iron oxide nanoparticles functionalized with an antibody against a cell surface marker of senescent cells (CD26), and loaded with the senolytic drug HSP90 inhibitor 17-DMAG (MNP@CD26@17D). We have documented its action against oxidative stress-induced senescent human fibroblasts, WI-38 and BJ cells, and anticancer drug-induced senescent cutaneous squamous cell carcinoma A431 cells, demonstrating for the first time that CD26 is a valid marker of senescence in cancer cells. A dual response to MNP@CD26@17D stimulation in senescent cells was revealed, namely, apoptosis-based early response (2 h treatment) and ferroptosis-based late response (24 h treatment). MNP@ CD26@17D-mediated ferroptosis might be executed by ferritinophagy as judged by elevated levels of the ferritinophagy marker NCOA4 and a decreased pool of ferritin. As 24 h treatment with MNP@CD26@17D did not induce hemolysis in human erythrocytes in vitro, this newly designed nanoplatform could be considered as an optimal multifunctional tool to target and eliminate senescent cells of skin origin, overcoming their apoptosis resistance.

Keywords: iron oxide nanoparticles ; CD26 ; HSP90 inhibitor ; drug-induced senescence ; skin cells ; senolysis

Purchased from AmBeed:

Alternative Products

Product Details of Tanespimycin

CAS No. :75747-14-7
Formula : C31H43N3O8
M.W : 585.69
SMILES Code : C=CCNC1=C2C(C(NC(/C(C)=C/C=C\[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C2)C)OC)O)C)OC(N)=O)OC)=O)=CC1=O)=O
Synonyms :
17-AAG; NSC 330507; 17-AAG, 17 AAG, 17AAG, BAY 57-9352, BAY 579352, BAY579352, KOS-953, KOS-953, KOS-953, Tanespimycin
MDL No. :MFCD04973892

Safety of Tanespimycin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Tanespimycin

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
DU145 human prostate cancer cells 230 nM 72 h To evaluate the growth inhibitory effect of SMA-tanespimycin micelles on DU145 human prostate cancer cells, results showed an IC50 of 230 nM. PMC3195848
HeLa cells 500 nM 18 h To study the effect of 17-AAG on Hsp90 conformation, results showed that 17-AAG induced conformational changes in Hsp90, including the closing of the ATP-binding pocket and increased interaction between the NTD and MD. PMC5012217
HCC827 0.25 µM 72 h To observe the effect of HSP90 inhibitor 17AAG on HCC827 cells, results showed that p53 remained constant in 3D conditions but was activated in 2D conditions. PMC6068345
A549 0.25 µM 72 h To observe the effect of HSP90 inhibitor 17AAG on A549 cells, results showed that HSP60 was significantly upregulated in 3D conditions. PMC6068345
H441 0.25 µM 72 h To observe the effect of HSP90 inhibitor 17AAG on H441 cells, results showed that p53 was activated in 3D conditions but remained unchanged in 2D conditions. PMC6068345
Leishmania mexicana promastigotes 2 μM, 10 μM, 25 μM 2 h To investigate the effects of Hsp90 inhibition on nascent protein synthesis in Leishmania mexicana. The results showed that 25 μM tanespimycin significantly decreased nascent protein synthesis, indicating that Hsp90 inhibition significantly affects protein translation. PMC8125071
Leishmania mexicana promastigotes 50 μM 1 h, 4 h To assess the temporal effect of tanespimycin treatment on global protein synthesis in Leishmania mexicana. The results showed that 4 h of Hsp90 inhibition significantly decreased global nascent protein synthesis, indicating that severe Hsp90 inhibition affects protein translation. PMC8125071
Z138 cells 0.5 and 1.0 µM 24 h To evaluate the effect of Tanespimycin on Z138 cells, results showed that Tanespimycin significantly inhibited the expression of MYC and CDK9 and induced cell apoptosis. PMC10848414
HT29 colon adenocarcinoma cells 62.5 nM 8 h To investigate changes in protein complexes following HSP90 inhibition, results showed limited changes in protein complex distribution after HSP90 inhibition. PMC9898794

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
nude mice subcutaneous DU145 human prostate cancer tumor xenografts tail vein injection 10 mg/kg single dose, lasting 23 days To evaluate the anti-cancer efficacy of SMA-tanespimycin micelles in nude mice bearing subcutaneous DU145 human prostate cancer tumor xenografts, results showed significant tumor growth inhibition. PMC3195848

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00779428 Advanced Malignancies PHASE2 COMPLETED 2025-07-13 Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States Less <<
NCT00773344 Solid Tumors|Breast Cancer PHASE1|PHASE2 COMPLETED 2025-08-09 Premiere Oncology Of Arizona, ... More >>Scottsdale, Arizona, 85260, United States|Arizona Cancer Center, Tucson, Arizona, 85724, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.71mL

0.34mL

0.17mL

8.54mL

1.71mL

0.85mL

17.07mL

3.41mL

1.71mL

References

 

Historical Records

Categories